Harmony Biosciences has announced the US Food and Drug Administration (FDA) has approved...
- FDA approves first non-controlled substance narcolepsy drug
- AstraZeneca and Merck’s Lynparza continues to perform well in ovarian cancer
- Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasis
- Progress made in developing first Chlamydia vaccine
- Explanation found for high mortality in breast cancer patients taking aspirin
FDA approves first non-controlled substance narcolepsy drug
Harmony Biosciences has announced the US Food and Drug Administration (FDA) has approved Wakix (pitolisant) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy.
Genentech gets FDA approval for tumour-agnostic drug Rozlytrek
The US Food and Drug Administration (FDA) has approved Roche division Genentech’s tumour-agnostic drug Rozlytrek, which targets a specific genetic defect called neurotrophic tyrosine receptor kinase (NTRK).
AstraZeneca and Merck’s Lynparza continues to perform well in ovarian cancer
AstraZeneca and Merck have announced that Lynparza (olaparib), the primary product in their ongoing oncology collaboration, has performed better than the standard of care as a first line maintenance treatment for patients with ovarian cancer, regardless of BRCA status.
Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasis
Eli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis.
AstraZeneca announces breakthrough therapy status for Calquence in CLL
AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL).
Boehringer partners with MD Anderson on virtual R&D centre
Boehringer Ingelheim has collaborated with The University of Texas MD Anderson Cancer Center to create a joint Virtual Research and Development Center focused on oncology research.
Roche’s IMvigor 130 study reads a positive result for co-primary endpoint in bladder cancer
Phase III trial was for the previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Progress made in developing first Chlamydia vaccine
Researchers from Statens Serum Institut (SSI), Denmark, and Imperial College London have published promising results from the first clinical trial of a vaccine for Chlamydia, the most common sexually transmitted disease.
Explanation found for high mortality in breast cancer patients taking aspirin
Researchers from the University of North Carolina (UNC) at Chapel Hill, US, have identified that wide variations in the mortality risk of breast cancer patients taking aspirin could be related to the DNA methylation profile in their tumours or peripheral blood.
China approves Gilead’s HIV-1 drug candidate Biktarvy
The China National Medical Products Administration (NMPA) has approved Gilead Sciences’ Biktarvy, a once-daily single-tablet regimen (STR) to treat HIV-1 infection.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.